Targeting epigenetics and using nanotechnology to prevent narrowing of blood vessels after surgery
Epigenetic targeting and nanoplatform-enabled local drug delivery - a two-pronged approach to stenosis prevention after vascular surgery
This study is looking at a new way to help prevent problems after vascular surgeries, like bypass grafting, by using a special treatment that targets a factor in the body that can cause blood vessels to narrow, which could lead to better recovery for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10995347 on NIH RePORTER |
What this research studies
This research focuses on preventing complications after vascular surgeries, such as bypass grafting, which often fail due to a condition called neointimal hyperplasia (IH). The study investigates the role of an epigenetic factor, DOT1L, which contributes to the development of IH by affecting vascular smooth muscle cells. By using a specially designed nanoplatform called Epi^NanoPaint, the researchers aim to deliver a targeted drug that inhibits DOT1L, potentially reducing the risk of vessel narrowing post-surgery. The approach is based on promising results from animal models, indicating that this method could improve surgical outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing vascular surgeries, particularly those at risk of developing neointimal hyperplasia.
Not a fit: Patients who have not undergone vascular surgery or those with conditions unrelated to vascular health may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the rates of complications and failures in vascular surgeries, leading to better long-term outcomes for patients.
How similar studies have performed: Other research has shown success in using targeted epigenetic therapies and nanotechnology for similar vascular conditions, indicating a promising avenue for this approach.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Guo, Lianwang — University of Virginia
- Study coordinator: Guo, Lianwang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.